Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.


Dubai Police launch 'Fit Zone 2025' to support inmates' health
Abu Dhabi to host global pledging event for polio eradication
H.H. Sheikh Hamdan congratulates Dubai's first Student Council
Abu Dhabi Crown Prince to lead UAE delegation at APEC Summit
UAE condemns Israeli Knesset move to annex West Bank
UAE breaks ground on world’s largest solar and battery project
AED 500 million endowment to support Arab Reading Challenge
Sharjah to enforce new lane rules for bikes, trucks and buses
Tunisian twins crowned Arab Reading Champions
Dubai simplifies permit process for Emirati villas
UAE extends deadline to obtain Advertiser Permit
Abu Dhabi Police launch 'Be Cautious' cybersecurity campaign
Sheikh Tahnoon meets US Special Envoy Witkoff, Kushner
New partnership strengthens Dubai’s drive for inclusive education
Traffic diversions in International City for Dubai Metro Blue Line works
UAE strengthens cooperation on energy transition with G20 countries
UAE welcomes Pakistan-Afghanistan ceasefire agreement
UAE President congratulates Japan's Takaichi on winning historic vote
Ajman rolls out smart speed limiters in taxis
UAE launches platform 'Amen' to keep a check on media
